Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01454934




Registration number
NCT01454934
Ethics application status
Date submitted
13/10/2011
Date registered
19/10/2011
Date last updated
22/06/2023

Titles & IDs
Public title
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Scientific title
Secondary ID [1] 0 0
E7389-G000-302
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-Small Cell Lung Cancer (NSCLC) 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Eribulin
Treatment: Drugs - TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed

Experimental: Arm A -

Active Comparator: Arm B -


Treatment: Drugs: Eribulin
Administration of eribulin mesylate at a dose of 1.4 mg/m2 i.v. over 2 to 5 minutes on Days 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.

Treatment: Drugs: TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
Vinorelbine 30 mg/m2 i.v. on Day 1, every 7 days
Gemcitabine 1250 mg/m2 i.v. on Days 1 and 8, every 21 days
Docetaxel 75 mg/m2 i.v. on Day 1 every 21 days
Pemetrexed 500 mg/m2 i.v. on Day 1 every 21 days (nonsquamous histology only).
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Randomization (Day 1) until date of death from any cause, or 37 months
Secondary outcome [1] 0 0
Progression Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST)
Timepoint [1] 0 0
Randomization (Day 1) until date of disease progression or death (whichever occurred first), or 37 months
Secondary outcome [2] 0 0
Objective Response Rate (ORR)
Timepoint [2] 0 0
Randomization (Day 1) to CR or PR

Eligibility
Key inclusion criteria
Inclusion:

Subjects must meet all of the following criteria to be included in this study:

1. Histologically or cytologically confirmed diagnosis of NSCLC.

2. Documented evidence of advanced NSCLC not amenable to surgery or radiotherapy.

3. Confirmation of the presence or absence of EGFR mutations prior to study enrolment in
all subjects.

4. Subjects must have received at least two prior regimens for advanced NSCLC, which
should have included a platinum-based regimen and, in all subjects with tumors
harbouring EGFR mutations, an EGFR TKI.

5. Radiographic evidence of disease progression on, or after, the last anti-cancer
regimen prior to study entry.

6. Presence of measurable disease.

7. ECOG performance status of 0, 1, or 2.

8. Adequate bone marrow

9. Adequate renal function.

10. Adequate liver function.

11. Female subjects of child-bearing potential must agree to use two forms of highly
effective contraception.

12. Male subjects and their female partners who are of child-bearing potential must agree
to use two forms of highly effective contraception.

13. Voluntary agreement to provide written informed consent and the willingness and
ability to comply with all aspects of the protocol.

14. Males or females aged at least 18 years (or any age greater than 18 years as
determined by country legislation) at the time of informed consent.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion:

Subjects who meet any of the following criteria will be excluded from this study:

1. Subjects who have received any anti-cancer therapy within 14 days, or five half-lives
of the drug (whichever is longer), prior to randomization.

2. Subjects who have not recovered from toxicities as a result of prior anti-cancer
therapy to less than Grade 2.

3. Subjects who have previously been treated, or participated in a study with eribulin,
whether treated with eribulin or not. The TPC option must not include the same agent
which the subject received in a prior regimen.

4. Peripheral neuropathy more than CTCAE Grade 2.

5. Significant cardiovascular impairment.

6. Subjects with a high probability of Long QT Syndrome, or QTc interval >500 ms.

7. Subjects with brain or subdural metastases are not eligible, unless the metastases are
asymptomatic and do not require treatment or have been adequately treated by local
therapy.

8. Any serious concomitant illness.

9. Known HIV positive, or have an infection requiring treatment.

10. Any malignancy that required treatment, or has shown evidence of recurrence (except
for NSCLC, non-melanoma skin cancer, or histologically confirmed complete excision of
carcinoma in-situ) during the 5 years prior to study entry.

11. Female subjects must not be pregnant, and must not be breastfeeding.

12. Hypersensitivity to either HalB or HalB chemical derivatives or both, or to any of the
excipients of the eribulin formulation.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/12/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
2/05/2016
Sample size
Target
Accrual to date
Final
540
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
- Herston
Recruitment hospital [2] 0 0
- Frankston
Recruitment postcode(s) [1] 0 0
- Herston
Recruitment postcode(s) [2] 0 0
- Frankston
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
New Hampshire
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
Oregon
Country [10] 0 0
United States of America
State/province [10] 0 0
Washington
Country [11] 0 0
United States of America
State/province [11] 0 0
Wisconsin
Country [12] 0 0
France
State/province [12] 0 0
Bas Rhin
Country [13] 0 0
France
State/province [13] 0 0
Bouches-du-Rhone
Country [14] 0 0
France
State/province [14] 0 0
Bouches-duRhone
Country [15] 0 0
France
State/province [15] 0 0
Gironde
Country [16] 0 0
France
State/province [16] 0 0
Haute Garonne
Country [17] 0 0
France
State/province [17] 0 0
Haute Vienne
Country [18] 0 0
France
State/province [18] 0 0
Ille Et Vilaine
Country [19] 0 0
France
State/province [19] 0 0
Loire Atlantique
Country [20] 0 0
France
State/province [20] 0 0
Nord
Country [21] 0 0
France
State/province [21] 0 0
Paris
Country [22] 0 0
France
State/province [22] 0 0
Rhone
Country [23] 0 0
France
State/province [23] 0 0
Val De Marne
Country [24] 0 0
Germany
State/province [24] 0 0
Bayern
Country [25] 0 0
Germany
State/province [25] 0 0
Nordrhein Westfalen
Country [26] 0 0
Germany
State/province [26] 0 0
Rheinland Pfalz
Country [27] 0 0
Germany
State/province [27] 0 0
Sachsen Anhalt
Country [28] 0 0
Hong Kong
State/province [28] 0 0
Hong Kong
Country [29] 0 0
Italy
State/province [29] 0 0
Lucca
Country [30] 0 0
Italy
State/province [30] 0 0
Milano
Country [31] 0 0
Italy
State/province [31] 0 0
Pordenone
Country [32] 0 0
Italy
State/province [32] 0 0
Cremona
Country [33] 0 0
Italy
State/province [33] 0 0
Siena
Country [34] 0 0
Japan
State/province [34] 0 0
Aichi-Ken
Country [35] 0 0
Japan
State/province [35] 0 0
Chiba-Ken
Country [36] 0 0
Japan
State/province [36] 0 0
Fukuoka-Ken
Country [37] 0 0
Japan
State/province [37] 0 0
Hiroshima-Ken
Country [38] 0 0
Japan
State/province [38] 0 0
Hokkaido
Country [39] 0 0
Japan
State/province [39] 0 0
Hygo-Ken
Country [40] 0 0
Japan
State/province [40] 0 0
Hyogo-ken
Country [41] 0 0
Japan
State/province [41] 0 0
Miyagi-Ken
Country [42] 0 0
Japan
State/province [42] 0 0
Nigata-Ken
Country [43] 0 0
Japan
State/province [43] 0 0
Okayama-Ken
Country [44] 0 0
Japan
State/province [44] 0 0
Osaka-Fu
Country [45] 0 0
Japan
State/province [45] 0 0
Shizuoka-Ken
Country [46] 0 0
Japan
State/province [46] 0 0
Tokyo-to
Country [47] 0 0
Japan
State/province [47] 0 0
Tokyo-To
Country [48] 0 0
Japan
State/province [48] 0 0
Yamaguchi-Ken
Country [49] 0 0
Japan
State/province [49] 0 0
Kitaadachi-gun
Country [50] 0 0
Korea, Republic of
State/province [50] 0 0
Gyeonggi-do
Country [51] 0 0
Korea, Republic of
State/province [51] 0 0
Korea
Country [52] 0 0
Poland
State/province [52] 0 0
Gdansk
Country [53] 0 0
Poland
State/province [53] 0 0
Mrozy
Country [54] 0 0
Poland
State/province [54] 0 0
Otwock
Country [55] 0 0
Poland
State/province [55] 0 0
Sczedin
Country [56] 0 0
Poland
State/province [56] 0 0
Warsazawa
Country [57] 0 0
Russian Federation
State/province [57] 0 0
Barnaul
Country [58] 0 0
Russian Federation
State/province [58] 0 0
Novosibirsk
Country [59] 0 0
Russian Federation
State/province [59] 0 0
Saint Petersburg
Country [60] 0 0
Singapore
State/province [60] 0 0
Singapore
Country [61] 0 0
Spain
State/province [61] 0 0
Barcelona
Country [62] 0 0
Spain
State/province [62] 0 0
Navarra
Country [63] 0 0
Spain
State/province [63] 0 0
Madrid
Country [64] 0 0
Taiwan
State/province [64] 0 0
Taichung
Country [65] 0 0
Taiwan
State/province [65] 0 0
Tainan
Country [66] 0 0
Taiwan
State/province [66] 0 0
Taipei City
Country [67] 0 0
Taiwan
State/province [67] 0 0
Taipei
Country [68] 0 0
United Kingdom
State/province [68] 0 0
Greater London
Country [69] 0 0
United Kingdom
State/province [69] 0 0
Greater Manchester
Country [70] 0 0
United Kingdom
State/province [70] 0 0
Surrey

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Eisai Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a randomized, open-label, multicenter, Phase 3 study, comparing efficacy and safety
of eribulin with TPC in subjects with advanced and disease progression following at least two
prior regimens for advanced disease, which should have included a platinum-based regimen.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01454934
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries